Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biol Res Nurs ; 14(2): 171-9, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21586497

RESUMO

Obesity is a growing health care concern with implications for cardiovascular disease (CVD). Obesity and CVD morbidity and mortality are highly prevalent among African American women. This pilot study examined the association between obesity and the traditional and emerging CVD risk factors in a sample of African American women. Participants comprised 48 women (27 obese, 21 normal weight) aged 18-45. with no known history of CVD. The women completed demographic and 7-day physical activity recall questionnaires. Height and weight were used to determine body mass index (BMI). Hypertension risk was assessed using the average of two resting blood pressure (BP) measurements. Lipid profile, blood glucose, fibrinogen, high-sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor-1 (PAI-1), soluble intercellular adhesion molecule-1 (sICAM-1), and E-selectin (eSel) levels were assessed using fasting blood samples. Laboratory findings were interpreted using the American Diabetes Association (ADA) and Adult Treatment Panel (ATP) III reference guidelines as well as manufacturers' reference ranges for the novel CVD risk factors. The most common traditional risk factors were physical inactivity (72.9%), positive family history of CVD (58.3%), and obesity (56.3%). Obese individuals had elevated systolic BP (p = .0002), diastolic BP (p = .0007) and HDL-cholesterol (p = .01), triglyceride (p = .02), hs-CRP (p = .002), and fibrinogen (p = .01), when compared with normal-weight women. The findings suggest an association between obesity and higher prevalence of both traditional and emerging CVD risk factors in young African American women.


Assuntos
Negro ou Afro-Americano , Doenças Cardiovasculares/etnologia , Obesidade/etnologia , Pressão Sanguínea , Índice de Massa Corporal , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/fisiopatologia , Exercício Físico , Feminino , Humanos , Obesidade/sangue , Obesidade/complicações , Obesidade/fisiopatologia , Projetos Piloto , Fatores de Risco , Inquéritos e Questionários
2.
J Cardiovasc Electrophysiol ; 22(2): 210-3, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20561106

RESUMO

We describe the case of a 43-year-old male with cardiac sarcoidosis and ventricular tachycardia storm successfully treated with catheter ablation and immunosuppression. Antiarrhythmics alone, and in combination with immusuppressive agents, failed to successfully manage the ventricular tachycardia episodes. Catheter ablation in conjunction with immunosuppression proved to be the most successful treatment strategy. The reported efficacy of catheter ablation for ventricular tachycardia in cardiac sarcoidosis is variable.


Assuntos
Cardiomiopatias/terapia , Ablação por Cateter/métodos , Imunossupressores/uso terapêutico , Sarcoidose/complicações , Taquicardia Ventricular/complicações , Taquicardia Ventricular/terapia , Adulto , Cardiomiopatias/complicações , Terapia Combinada , Humanos , Masculino , Sarcoidose/terapia , Resultado do Tratamento
3.
J Mol Cell Cardiol ; 44(2): 405-10, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18048055

RESUMO

Transgenic expression of enhanced green fluorescent protein (eGFP) in myocardium can result in cardiac dysfunction and cardiomyopathy, presumably through toxic effects that disrupt normal cellular signaling. The multifunctional Ca(2+)- and calmodulin-dependent protein kinase II (CaMKII) is widely expressed in myocardium and CaMKII activity is increased in human and animal models of cardiomyopathy, so we hypothesized that increased CaMKII activity is important for cardiomyopathy due to transgenic expression of eGFP. Here we report that cardiomyocyte-delimited eGFP over-expression causes increased CaMKII activity that predicts left ventricular dilation and dysfunction. On the other hand, transgenic co-expression of a CaMKII inhibitory peptide with eGFP prevents eGFP-mediated left ventricular dilation and dysfunction. These findings suggest that increased CaMKII activity is a critical pathological signal in transgenic cardiomyopathy due to eGFP over-expression.


Assuntos
Proteína Quinase Tipo 2 Dependente de Cálcio-Calmodulina/antagonistas & inibidores , Cardiomiopatias/enzimologia , Proteínas de Fluorescência Verde/metabolismo , Animais , Cardiomiopatias/fisiopatologia , Ventrículos do Coração/efeitos dos fármacos , Ventrículos do Coração/patologia , Ventrículos do Coração/fisiopatologia , Hipertrofia , Camundongos , Camundongos Transgênicos , Tamanho do Órgão/efeitos dos fármacos , Peptídeos/farmacologia , Função Ventricular Esquerda/efeitos dos fármacos
4.
Circulation ; 114(13): 1352-9, 2006 Sep 26.
Artigo em Inglês | MEDLINE | ID: mdl-16982937

RESUMO

BACKGROUND: Activation of cellular Ca2+ signaling molecules appears to be a fundamental step in the progression of cardiomyopathy and arrhythmias. Myocardial overexpression of the constitutively active Ca2+-dependent phosphatase calcineurin (CAN) causes severe cardiomyopathy marked by left ventricular (LV) dysfunction, arrhythmias, and increased mortality rate, but CAN antagonist drugs primarily reduce hypertrophy without improving LV function or risk of death. METHODS AND RESULTS: We found that activity and expression of a second Ca2+-activated signaling molecule, calmodulin kinase II (CaMKII), were increased in hearts from CAN transgenic mice and that CaMKII-inhibitory drugs improved LV function and suppressed arrhythmias. We devised a genetic approach to "clamp" CaMKII activity in CAN mice to control levels by interbreeding CAN transgenic mice with mice expressing a specific CaMKII inhibitor in cardiomyocytes. We developed transgenic control mice by interbreeding CAN transgenic mice with mice expressing an inactive version of the CaMKII-inhibitory peptide. CAN mice with CaMKII inhibition had reduced risk of death and increased LV and ventricular myocyte function and were less susceptible to arrhythmias. CaMKII inhibition did not reduce transgenic overexpression of CAN or expression of endogenous CaMKII protein or significantly reduce most measures of cardiac hypertrophy. CONCLUSIONS: CaMKII is a downstream signal in CAN cardiomyopathy, and increased CaMKII activity contributes to cardiac dysfunction, arrhythmia susceptibility, and longevity during CAN overexpression.


Assuntos
Arritmias Cardíacas/enzimologia , Calcineurina/fisiologia , Sinalização do Cálcio , Proteínas Quinases Dependentes de Cálcio-Calmodulina/fisiologia , Morte Súbita Cardíaca/etiologia , Disfunção Ventricular Esquerda/enzimologia , Sequência de Aminoácidos , Animais , Animais Recém-Nascidos , Apoptose , Arritmias Cardíacas/genética , Arritmias Cardíacas/prevenção & controle , Benzilaminas/farmacologia , Benzilaminas/uso terapêutico , Calcineurina/biossíntese , Proteína Quinase Tipo 2 Dependente de Cálcio-Calmodulina , Proteínas Quinases Dependentes de Cálcio-Calmodulina/antagonistas & inibidores , Proteínas Quinases Dependentes de Cálcio-Calmodulina/biossíntese , Proteínas Quinases Dependentes de Cálcio-Calmodulina/genética , Células Cultivadas/efeitos dos fármacos , Células Cultivadas/fisiologia , Morte Súbita Cardíaca/prevenção & controle , Modelos Animais de Doenças , Indução Enzimática , Hipertrofia Ventricular Esquerda/tratamento farmacológico , Hipertrofia Ventricular Esquerda/enzimologia , Hipertrofia Ventricular Esquerda/genética , Isoproterenol/toxicidade , Camundongos , Camundongos Transgênicos , Dados de Sequência Molecular , Contração Miocárdica/efeitos dos fármacos , Miócitos Cardíacos/efeitos dos fármacos , Miócitos Cardíacos/fisiologia , Fragmentos de Peptídeos/genética , Fragmentos de Peptídeos/fisiologia , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , Ratos , Sulfonamidas/farmacologia , Sulfonamidas/uso terapêutico , Disfunção Ventricular Esquerda/tratamento farmacológico , Disfunção Ventricular Esquerda/genética
5.
Heart Rhythm ; 2(6): 634-40, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15922273

RESUMO

BACKGROUND: Multifunctional Ca2+/calmodulin-dependent protein kinase II (CaMKII) is abundant in myocardium. CaMKII activity is augmented by catecholamine stimulation, which enhances AV nodal conduction, suggesting the hypothesis that CaMKII also contributes to AV nodal conduction properties. OBJECTIVES: The purpose of this study was to test the potential role of CaMKII in regulating AV nodal conduction in heart. METHODS: We developed a novel mouse with genetic CaMKII inhibition by cardiac-specific expression of autocamtide 3 inhibitory peptide (AC3-I) mimicking a conserved sequence of the CaMKII regulatory domain. We also engineered a control transgenic mouse with cardiac expression of an inactive, scrambled version of AC3-I (autocamtide 3 control peptide [AC3-C]) and performed electrophysiologic measurements in vivo and in Langendorff-perfused isolated hearts. RESULTS: AC3-I and AC3-C were abundantly expressed in AV nodal cells. AC3-I mice with implanted ECG telemeters showed enhanced Wenckebach-type AV conduction block after isoproterenol (present in 9/9 mice) compared with AC3-C mice (present in 1/5 mice, P = .005). Intracardiac recordings showed significant PR and AH interval prolongation in AC3-I mice at baseline and after isoproterenol compared with AC3-C mice. HV durations were not different. Langendorff-perfused AC3-I hearts had significantly prolonged Wenckebach cycle lengths and AV nodal effective refractory periods compared with AC3-C hearts, whereas sinus node recovery time and left ventricular effective refractory times were similar between these genotypes. CONCLUSIONS: These studies define CaMKII as a critical determinant of normal and catecholamine-stimulated AV nodal conduction responses.


Assuntos
Nó Atrioventricular/fisiologia , Proteínas Quinases Dependentes de Cálcio-Calmodulina/fisiologia , Análise de Variância , Animais , Proteína Quinase Tipo 2 Dependente de Cálcio-Calmodulina , Regulação Enzimológica da Expressão Gênica , Camundongos , Camundongos Transgênicos , Transdução de Sinais
6.
Nat Med ; 11(4): 409-17, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15793582

RESUMO

Beta-adrenergic receptor (betaAR) stimulation increases cytosolic Ca(2+) to physiologically augment cardiac contraction, whereas excessive betaAR activation causes adverse cardiac remodeling, including myocardial hypertrophy, dilation and dysfunction, in individuals with myocardial infarction. The Ca(2+)-calmodulin-dependent protein kinase II (CaMKII) is a recently identified downstream element of the betaAR-initiated signaling cascade that is linked to pathological myocardial remodeling and to regulation of key proteins involved in cardiac excitation-contraction coupling. We developed a genetic mouse model of cardiac CaMKII inhibition to test the role of CaMKII in betaAR signaling in vivo. Here we show CaMKII inhibition substantially prevented maladaptive remodeling from excessive betaAR stimulation and myocardial infarction, and induced balanced changes in excitation-contraction coupling that preserved baseline and betaAR-stimulated physiological increases in cardiac function. These findings mark CaMKII as a determinant of clinically important heart disease phenotypes, and suggest CaMKII inhibition can be a highly selective approach for targeting adverse myocardial remodeling linked to betaAR signaling.


Assuntos
Proteínas Quinases Dependentes de Cálcio-Calmodulina/fisiologia , Antagonistas Adrenérgicos beta/farmacologia , Animais , Arritmias Cardíacas/metabolismo , Cálcio/metabolismo , Proteína Quinase Tipo 2 Dependente de Cálcio-Calmodulina , Proteínas Quinases Dependentes de Cálcio-Calmodulina/antagonistas & inibidores , Baixo Débito Cardíaco , Cardiomegalia , Camundongos , Camundongos Transgênicos , Contração Miocárdica , Infarto do Miocárdio/metabolismo , Infarto do Miocárdio/fisiopatologia , Fosforilação , Remodelação Ventricular
7.
Am J Kidney Dis ; 41(6): 1247-56, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12776278

RESUMO

BACKGROUND: Potassium-rich cardioplegia has advantages over other cardioplegic solutions in preserving the myocardium during cardiopulmonary bypass, but it is avoided in patients with renal failure because of hyperkalemia. METHODS: We first determined the ability of intraoperative hemodialysis (IHD) to remove potassium during cardiopulmonary bypass with potassium-rich cardioplegia in 9 patients by measuring potassium levels in all dialysate and urine. We then studied 24 patients with renal failure, grouped with the 9 previous patients, to assess safety, rebound hyperkalemia, and patient outcome with this technique. RESULTS: In the first phase, 9 patients were administered 128 +/- 11 mmol of potassium in potassium-rich cardioplegia, and IHD removed 157 +/- 23 mmol. Urinary potassium excretion was only 10 +/- 3 mmol. Potassium removal occurred at a rate of 1.25 mmol/min with 0-mEq/L (mmol/L) potassium dialysate and a rate of 0.75 mmol/min with 3.0-mEq/L (mmol/L) potassium dialysate. In all 33 patients, successful initiation of cardiac rhythm occurred after cardiopulmonary bypass, and 5 patients had cardiac arrhythmias possibly from hypokalemia. In the next 24 hours, 5 dialysis-dependent patients developed hyperkalemia (potassium > 5.2 mEq/L [mmol/L]) requiring hemodialysis. Postoperative hemodialysis was delayed 2 to 3 days in the other patients. The overall death rate was 24% at 30 days. CONCLUSION: IHD effectively and safely removes potassium administered during potassium-rich cardioplegia during cardiopulmonary bypass in patients with renal failure and prevents postoperative hyperkalemia in the majority of patients. Overall mortality in patients with acute and chronic renal failure undergoing cardiac surgery is high irrespective of control of potassium balance in these patients.


Assuntos
Soluções Cardioplégicas/farmacologia , Ponte Cardiopulmonar , Parada Cardíaca Induzida/métodos , Cuidados Intraoperatórios , Potássio/farmacologia , Diálise Renal , Idoso , Ponte Cardiopulmonar/instrumentação , Soluções Cristaloides , Desenho de Equipamento , Feminino , Cardiopatias/complicações , Cardiopatias/cirurgia , Humanos , Hiperpotassemia/induzido quimicamente , Hiperpotassemia/prevenção & controle , Complicações Intraoperatórias/induzido quimicamente , Complicações Intraoperatórias/prevenção & controle , Soluções Isotônicas , Masculino , Traumatismo por Reperfusão Miocárdica/prevenção & controle , Substitutos do Plasma/administração & dosagem , Complicações Pós-Operatórias/prevenção & controle , Potássio/administração & dosagem , Potássio/urina , Diálise Renal/instrumentação , Insuficiência Renal/sangue , Insuficiência Renal/complicações , Insuficiência Renal/terapia , Resultado do Tratamento
8.
Pacing Clin Electrophysiol ; 25(11): 1652-5, 2002 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-12494628

RESUMO

A 47-year-old man had an ICD system with epicardial and endocardial components and an abdominal generator placed in 1990 following a cardiac arrest. Ten years later his BT10 lead was amputated due to an insulation defect, and he received a new pectoral generator with transvenous leads. A few months later he developed fevers, chills, and bacteremia. Evaluation demonstrated migration of the entire BT10 lead into the right atrium. Complete surgical explantation was required and the bacteremia resolved. This case illustrates the importance of solid anchoring of distal lead components following generator removal and the potential complication of intravascular lead migration.


Assuntos
Desfibriladores Implantáveis/efeitos adversos , Migração de Corpo Estranho/complicações , Infecções Relacionadas à Prótese/etiologia , Infecções Estreptocócicas/etiologia , Streptococcus mutans , Abdome , Humanos , Masculino , Pessoa de Meia-Idade
9.
Circulation ; 105(6): 770-4, 2002 Feb 12.
Artigo em Inglês | MEDLINE | ID: mdl-11839636

RESUMO

BACKGROUND: We have shown that the calmodulin inhibitor W-7 suppresses torsade de pointes (TdP) without shortening the QT interval, which is consistent with other findings that QT prolongation, per se, is insufficient to generate TdP. ECGs were analyzed from a well-characterized animal model of TdP to identify more reliable predictors of this life-threatening ventricular arrhythmia. METHODS AND RESULTS: TdP was induced using methoxamine and clofilium in 12 of 14 rabbits pretreated with vehicle control, whereas pretreatment with W-7 (50 micromol/kg), an inhibitor of the intracellular Ca2+-binding protein calmodulin, significantly suppressed TdP induction (1 of 11 rabbits with TdP, P<0.001). W-7 did not affect heart rate, increases in QT intervals, or dispersion compared with measurements in vehicle-treated control animals. However, a progressive and significant increase in the ratio of U-wave to T-wave amplitude (UTA) occurred before TdP onset in control animals, and this was prevented by W-7. CONCLUSIONS: Selective suppression of TdP inducibility by W-7, without shortening the duration of cardiac repolarization, allowed identification of the UTA ratio as a new electrocardiographic index for predicting TdP onset. These findings are consistent with the idea that prolonged repolarization is not the proximate cause of arrhythmia initiation, and they suggest that an increased UTA ratio reflects activation of intracellular Ca2+/calmodulin-dependent processes that are required for triggering TdP in this model.


Assuntos
Arritmias Cardíacas , Calmodulina/antagonistas & inibidores , Eletrocardiografia/efeitos dos fármacos , Sulfonamidas , Torsades de Pointes/diagnóstico , Torsades de Pointes/prevenção & controle , Animais , Arritmias Cardíacas/complicações , Arritmias Cardíacas/fisiopatologia , Modelos Animais de Doenças , Inibidores Enzimáticos , Frequência Cardíaca/efeitos dos fármacos , Masculino , Metoxamina , Bloqueadores dos Canais de Potássio , Valor Preditivo dos Testes , Compostos de Amônio Quaternário , Coelhos , Processamento de Sinais Assistido por Computador , Torsades de Pointes/etiologia , Torsades de Pointes/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...